_____________________________________________________________________________________________________ *Corresponding author: E-mail: maurizio.arico@meyer.it; Journal of Advances in Medical and Pharmaceutical Sciences 20(3): 1-8, 2019; Article no.JAMPS.49029 ISSN: 2394-1111 Use of Micafungin for the Management of a Cluster of Invasive Aspergillosis in Children with Cancer Désirée Caselli 1* , Luisa Galli 2 , Annalisa Tondo 1 , Daniela Cuzzubbo 1 , Tommaso Casini 1 , Lorena Di Simone 3 , Angela Tamburini 1 , Franco Bambi 4 , Fabio Tucci 1 and Maurizio Aricò 1* 1 Department of Hematology and Oncology, A.O.U. / Meyer Children Hospital, Florence, Italy. 2 Department of Health Science, University of Florence, Infectious Diseases, A.O.U. / Meyer Children Hospital, Florence, Italy. 3 Department of Pharmacy, A.O.U. / Meyer Children Hospital, Florence, Italy. 4 Department of Transfusion Medicine, A.O.U. / Meyer Children Hospital, Florence, Italy. Authors’ contributions This work was carried out in collaboration among all authors. Authors DC, LG and MA designed the study, wrote the protocol and wrote the first draft of the manuscript. Author FB supervised the laboratory investigation for control of mold contamination. Authors DC, DaCu, AT, AnTa and FT were in charge for patient care, collected the clinical data and performed the literature search. Author LDS performed the analysis of costs. All authors read and approved the final manuscript. Article Information DOI: 10.9734/JAMPS/2019/v20i330112 Editor(s): (1) Dr. Amr Ahmed El-Arabey, Pharmacology & Toxicology Department, Al-Azhar University, Egypt and University of Science and Technology of China (USTC), China. Reviewers: (1) A. Lamiaa Madkour, Cairo University, Egypt. (2) Massimo Berger, University of Turin, Italy. (3) Ikobho Ebenezer Howells, Niger Delta University Teaching Hospital, Nigeria. Complete Peer review History: http://www.sdiarticle3.com/review-history/49029 Received 02 March 2019 Accepted 11 May 2019 Published 17 May 2019 ABSTRACT Background: Progressive increase of the capacity to cure children with cancer makes their rescue from life-threatening infectious complications, such as invasive fungal infections, a compelling challenge. Local outbreak among patients at risk may occur, and the optimal strategy for their management, including prophylactic regimens, is not defined. Purpose: We describe our experience in the use of micafungin to break a cluster of invasive aspergillosis in children and adolescent with cancer. Original Research Article